ETISTP: An Enhanced Model for Brain Tumor Identification and Survival Time Prediction.
Shah Hussain1, Shahab Haider1, Sarmad Maqsood2
1Department of Computer Science, City University of Science and Information Technology, Peshawar 25000, Pakistan.
Diagnostics (Basel, Switzerland)
|May 16, 2023
Summary
This study introduces a new brain tumor survival prediction model (ETISTP) that uses tumor volume for improved accuracy. The enhanced model offers faster computation and better predictions than existing methods for glioma patients.
Area of Science:
- Medical imaging and diagnostics
- Computational oncology
- Artificial intelligence in healthcare
Background:
- Brain tumors, particularly gliomas, are a significant cause of cancer mortality globally.
- Accurate survival prediction is crucial for effective glioma treatment planning.
- Current survival prediction models often lack sufficient accuracy due to limitations in parameters used.
Purpose of the Study:
- To develop an enhanced brain tumor identification and survival time prediction (ETISTP) model.
- To improve the accuracy of survival prediction for glioma patients.
- To introduce tumor volume as a novel parameter in brain tumor survival prediction.
Main Methods:
- The ETISTP model integrates patient age, survival days, gross total resection (GTR) status, and tumor volume.
- Tumor volume computation and glioma grading are performed in parallel for efficiency.
- The model was evaluated against existing survival prediction methodologies.
Main Results:
- The ETISTP model demonstrated superior accuracy in predicting survival times compared to existing models.
- The integration of tumor volume significantly enhanced prediction performance.
- Parallel processing minimized computation time for tumor volume calculation and classification.
Conclusions:
- The ETISTP model represents a significant advancement in brain tumor survival prediction accuracy.
- Utilizing tumor volume is a key innovation for more precise prognostic assessments in glioma.
- The model's efficiency and accuracy offer potential benefits for clinical decision-making in neuro-oncology.


